• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Destruxin B

Destruxin B

Product ID D183745
Cas No. 2503-26-6
Purity ≥96%
Product Unit SizeCostQuantityStock
100 µg $102.00 In stock
1 mg $613.00 In stock
5 mg $2,453.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Destruxin B, a cyclic depsipeptide, is a secondary metabolite isolated from the fungus Metarhizium anisopliae. Each of the mycotoxins, destruxin A, B, and E, were individually found to display antitumor effects on leukemic cells in vitro. In addition, each destruxin was found to produce antiproliferative effects in colon cancer cells and to inhibit the migration and tube formation of human endothelial cells. Although the inhibition of vacuolar-type ATPase by destruxin B has been found to be weaker than bafilomycin A1, inhibition by destruxin B was found to be readily reversible, which makes it more useful as a probe of V-ATPase function. In human colorectal cancer cells destruxin B treatment resulted in suppressed proliferation and induced cell cycle arrest. Administration of destruxin B to human non-Hodgkin lumphoma cells resulted in apoptosis induced by attenuation of the mitochondrial membrane potential.

Product Info

Cas No.

2503-26-6

Purity

≥96%

Formula

C30H51N5O7

Formula Wt.

593.77

Chemical Name

Destruxin B

IUPAC Name

16-butan-2-yl-10,11,14-trimethyl-3-(2-methylpropyl)-13-propan-2-yl-4-oxa-1,8,11,14,17-pentazabicyclo[17.3.0]docosane-2,5,9,12,15,18-hexone

Synonym

MLS002702090; AC1L8LE6; MEGxm0_000393

Melting Point

230-240°C

Appearance

White powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

D183745 MSDS PDF

Info Sheet

D183745 Info Sheet PDF

References

Yeh CT, Rao YK, Ye M, et al. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging. Toxicol Appl Pharmacol. 2012 May 15;261(1):31-41. PMID: 22465936.

Odier F, Vey A, Bureau JP. In vitro effect of fungal cyclodepsipeptides on leukemic cells: study of destruxins A, B, and E. Biol Cell. 1992;74(3):267-271. PMID: 1628110.

Dornetshuber-Fleiss R, Heffeter P, Mohr T, et al. Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. Biochem Pharmacol. 2013 Aug 1;86(3):361-377. PMID: 23747344.

Muroi M, Shiragami N, Takatsuki A. Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1358-1365. PMID: 7802670.

Chao PZ, Chin YP, Hsu IU, et al. Apoptotic toxicity of destruxin B in human non-Hodgkin lymphoma cells. Toxicol In Vitro. 2013 Sep;27(6):1870-1876. PMID: 23751424.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • E5221

    Endothelin-2, human

    Endogenous peptide involved in vascular contrac...

    ≥95%
  • N582686

    L-(-)-Norepinephrine-(+)-bitartrate

    Endogenous hormone and neurotransmitter involve...

    ≥98%
  • S0501

    SB-939

    HDAC inhibitor.

    ≥98%
  • V2792

    VGX-1027

    TLR4 inhibitor.

    ≥98%
  • A985120

    AZD-0156

    Inhibitor of ATM.

    ≥98%
  • B0133

    Baicalin

    Flavone found in Scutellaria; prolyl oligopepti...

    ≥95%
  • C2800

    Chalcone

    Enone.

    ≥97%
  • A5035

    5-Aminosalicylic Acid

    Salicylic acid derivative; PPARγ agonist, pote...

    ≥98%
  • L960008

    LY-3177833

    Cdc7 inhibitor.

    ≥99%
  • C5645

    Colchicine

    Found in Colchicum; microtubule polymerization ...

    ≥97%
  • P0398

    Pazufloxacin Methanesulfonate

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • G124084

    GDC-0973

    MEK1 inhibitor.

    ≥99%
  • I7259

    Isoproterenol Hydrochloride

    β-adrenergic agonist.

    ≥98%
  • A6268

    Aprotinin

    Polypeptide; serine protease inhibitor.

    ≥ 5400 u/mg
  • P2510

    4-Phenylbutylisothiocyanate

    Synthetic ITC.

    ≥98%
  • C9809

    Cyclopiazonic Acid

    SERCA inhibitor.

    ≥98%, TLC
  • H0003

    H89

    PKA inhibitor, potential ROCK, S6K1, MSK1, PKB ...

    ≥98%
  • T3357

    Tioconazole

    Imidazole; 14-α demethylase inhibitor.

    ≥98%
  • L0250

    Laminin Peptide SIKVAV

    Laminin-derived hexapeptide.

    ≥98%
  • M5610

    Moclobemide

    MAO-A inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only